This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
case fatality | 199 |
fatality rate | 125 |
novel coronavirus | 108 |
granted medrxiv | 107 |
author funder | 107 |
copyright holder | 103 |
version posted | 103 |
public health | 100 |
confirmed cases | 82 |
made available | 80 |
international license | 78 |
coronavirus disease | 67 |
pandemic influenza | 67 |
fatality rates | 62 |
convalescent plasma | 61 |
south korea | 60 |
peer review | 60 |
social distancing | 58 |
medrxiv preprint | 56 |
pneumococcal pneumonia | 54 |
reproduction number | 50 |
respiratory syndrome | 48 |
fatality ratio | 47 |
acute respiratory | 47 |
united states | 43 |
time series | 43 |
risk factors | 43 |
severe acute | 41 |
school closure | 40 |
attack rate | 39 |
productivity losses | 39 |
posted may | 38 |
different countries | 38 |
health care | 37 |
total number | 37 |
influenza pandemic | 36 |
selection bias | 34 |
reported cases | 34 |
posted october | 34 |
crude cfr | 34 |
case incidence | 34 |
cord uid | 34 |
mortality rate | 34 |
doc id | 34 |
infectious disease | 33 |
severe cases | 32 |
infectious diseases | 31 |
growth rate | 31 |
adjusted cfr | 31 |
systematic review | 30 |
pandemic period | 28 |
age distribution | 28 |
clinical severity | 27 |
age group | 27 |
clinical characteristics | 26 |
intensive care | 25 |
seasonal influenza | 25 |
effective reproduction | 24 |
european countries | 24 |
cumulative number | 24 |
affected countries | 24 |
total cost | 24 |
across countries | 23 |
epidemiological characteristics | 23 |
infection fatality | 23 |
acquired pneumonia | 23 |
high risk | 22 |
world health | 22 |
reported deaths | 22 |
bacteremic pneumococcal | 22 |
publicly available | 22 |
per person | 21 |
syndrome coronavirus | 21 |
positive cases | 21 |
basic reproduction | 21 |
supplemental oxygen | 21 |
observational studies | 21 |
per capita | 21 |
health organization | 20 |
total costs | 19 |
simulation model | 19 |
national guidelines | 19 |
cfr ma | 19 |
diagnostic rate | 19 |
new cases | 19 |
new york | 18 |
symptom onset | 18 |
delay time | 18 |
first case | 18 |
diamond princess | 18 |
severity pandemics | 18 |
cumulative cases | 18 |
losses due | 18 |
related productivity | 17 |
general population | 17 |
age groups | 17 |
disease control | 17 |
cfr values | 17 |
tsd analysis | 17 |
distancing interventions | 17 |
adjusted cfrs | 17 |
life expectancy | 17 |
incubation period | 17 |
population density | 17 |
posted june | 17 |
middle east | 17 |
mainland china | 16 |
streptococcus pneumoniae | 16 |
death counts | 16 |
exponential growth | 16 |
total population | 16 |
target spo | 16 |
hospitalized patients | 16 |
cases reported | 16 |
years old | 15 |
control measures | 15 |
multistep model | 15 |
high severity | 15 |
per million | 15 |
countries regions | 15 |
deaths per | 15 |
classic cfr | 15 |
nan doi | 15 |
press freedom | 15 |
case data | 15 |
fatality risk | 15 |
standard deviation | 15 |
hubei province | 15 |
higher cfr | 15 |
avian influenza | 14 |
gdp per | 14 |
wbf model | 14 |
case numbers | 14 |
time delay | 14 |
population level | 14 |
per day | 14 |
supplementary table | 14 |
doubling interval | 14 |
outbreak duration | 14 |
relative cfr | 14 |
intervention strategies | 14 |
linear regression | 14 |
antiviral treatment | 14 |
clinical features | 14 |
princess cruise | 14 |
pandemic severity | 13 |
cruise ship | 13 |
may also | 13 |
death data | 13 |
studies reported | 13 |
health system | 13 |
contact tracing | 13 |
community contact | 13 |
conservative oxygen | 13 |
cohort study | 13 |
arima model | 13 |
asymptomatic cases | 13 |
infected individuals | 13 |
cfr estimates | 13 |
adult hiv | 12 |
hospital beds | 12 |
contact reduction | 12 |
seven countries | 12 |
spanish influenza | 12 |
cov infection | 12 |
symptomatic cases | 12 |
east respiratory | 12 |
severity categories | 12 |
testing capacity | 12 |
infected people | 12 |
gender differences | 12 |
low severity | 12 |
data collection | 12 |
transmission dynamics | 12 |
causal variables | 12 |
emergency response | 12 |
reported data | 12 |
even though | 12 |
italian cfr | 11 |
systematic reviews | 11 |
risk factor | 11 |
confidence interval | 11 |
tobacco use | 11 |
care unit | 11 |
attack rates | 11 |
cohort studies | 11 |
data sources | 11 |
infected patients | 11 |
male patients | 11 |
patients infected | 11 |
coronavirus pneumonia | 11 |
mitigation strategies | 11 |
hiv prevalence | 11 |
death rates | 11 |
case counts | 11 |
time period | 11 |
mortality rates | 11 |
severe disease | 11 |
health outcomes | 11 |
people aged | 11 |
health authorities | 11 |
high cfr | 11 |
respiratory infections | 11 |
protective equipment | 11 |
clinical research | 10 |
respiratory protection | 10 |
pneumococcal bacteremia | 10 |
sensitivity analyses | 10 |
cfr due | 10 |
pharmaceutical interventions | 10 |
global health | 10 |
coronavirus infections | 10 |
relative case | 10 |
statistical analysis | 10 |
sri lanka | 10 |
correlation coefficient | 10 |
united kingdom | 10 |
plasma treatment | 10 |
absolute reduction | 10 |
warm zone | 10 |
medical care | 10 |
rasch model | 10 |
death rate | 10 |
data available | 10 |
different age | 10 |
case series | 10 |
critically ill | 10 |
data points | 10 |
saarc countries | 10 |
highly effective | 10 |
real cfr | 10 |
survival interval | 10 |
johns hopkins | 9 |
calculated cfr | 9 |
using data | 9 |
outbreak magnitudes | 9 |
mechanical ventilation | 9 |
i will | 9 |
age structure | 9 |
patients dying | 9 |
statistically significant | 9 |
proposed hybrid | 9 |
outbreak start | 9 |
care systems | 9 |
clinical trial | 9 |
infection rates | 9 |
negative correlation | 9 |
sensitivity analysis | 9 |
health interventions | 9 |
total deaths | 9 |
cases per | 9 |
will depend | 9 |
crude cfrs | 9 |
five countries | 9 |
workforce reduction | 9 |
large number | 9 |
older people | 9 |
diagnosis interval | 9 |
virus disease | 9 |
inflammatory response | 9 |
lower cfr | 9 |
early phase | 9 |
influenza virus | 9 |
full text | 9 |
infected pneumonia | 9 |
confidence intervals | 9 |
many countries | 9 |
related deaths | 9 |
continuous school | 9 |
viral etiology | 9 |
reporting rates | 9 |
diabetes prevalence | 9 |
patients aged | 9 |
hybrid arima | 9 |
data analysis | 9 |
i i | 9 |
risk assessment | 9 |
observed cases | 9 |
infected persons | 9 |
personal protective | 9 |
virus infection | 9 |
effective interventions | 9 |
hong kong | 9 |
doubling time | 9 |
working group | 9 |
oxygen strategies | 8 |
rasch analysis | 8 |
different cfr | 8 |
ill patients | 8 |
biased due | 8 |
new zealand | 8 |
diagnosed cases | 8 |
reporting delay | 8 |
less likely | 8 |
care system | 8 |
causal interpretation | 8 |
target oxygen | 8 |
overall cfr | 8 |
level morbidities | 8 |
hyperimmune immunoglobulin | 8 |
disease outbreak | 8 |
two studies | 8 |
google maps | 8 |
identified cases | 8 |
health measures | 8 |
computed using | 8 |
global burden | 8 |
specific cfrs | 8 |
bias may | 8 |
mortality associated | 8 |
coronavirus diseases | 8 |
official data | 8 |
early stage | 8 |
immune response | 8 |
recovered cases | 8 |
affected province | 8 |
without permission | 8 |
cumulative incidence | 8 |
survivorship bias | 8 |
contaminated patients | 8 |
herd immunity | 8 |
cumulative deaths | 8 |
series forecasting | 8 |
days ago | 8 |
high case | 8 |
research networks | 8 |
cfr varied | 8 |
infected cases | 8 |
severe pandemic | 8 |
intervention strategy | 8 |
table shows | 8 |
hybrid model | 8 |
geographic risks | 8 |
prospective cohort | 8 |
hopkins university | 8 |
convalescent serum | 8 |
female patients | 8 |
modelling study | 8 |
one day | 8 |
fatality ratios | 8 |
epidemic growth | 8 |
previous studies | 8 |
epidemiological parameters | 8 |
health policy | 8 |
serial interval | 7 |
disease severity | 7 |
regression analysis | 7 |
given time | 7 |
mathematical modelling | 7 |
much higher | 7 |
increased mortality | 7 |
tests performed | 7 |
susceptible individual | 7 |
country specific | 7 |
cases will | 7 |
economic analysis | 7 |
lowest total | 7 |
regression tree | 7 |
clinical symptoms | 7 |
true cfr | 7 |
specific differences | 7 |
health systems | 7 |
older age | 7 |
local epidemic | 7 |
health emergency | 7 |
case detection | 7 |
shifted distribution | 7 |
mild cases | 7 |
care units | 7 |
clinical trials | 7 |
additional file | 7 |
combination therapy | 7 |
daily covid | 7 |
pdm infection | 7 |
income countries | 7 |
cumulative case | 7 |
emerging infectious | 7 |
april th | 7 |
per population | 7 |
infection rate | 7 |
eligibility criteria | 7 |
surveillance data | 7 |
seroprevalence data | 7 |
per country | 7 |
least one | 7 |
geographic risk | 7 |
gender difference | 7 |
distancing measures | 7 |
cfr across | 7 |
population age | 7 |
two weeks | 7 |
severe symptoms | 7 |
epidemic size | 7 |
antiviral drugs | 7 |
healthcare workers | 7 |
residual series | 7 |
prospective study | 7 |
sir model | 7 |
data set | 7 |
patient care | 7 |
respiratory tract | 7 |
allowed without | 7 |
death tolls | 7 |
term forecasts | 7 |
west africa | 7 |
posted april | 7 |
ifr values | 7 |
identified studies | 7 |
countries may | 7 |
estimated cfr | 7 |
country comparisons | 7 |
based analysis | 7 |
fatal cases | 7 |
urinary antigen | 7 |
reuse allowed | 7 |
testing data | 7 |
potential biases | 7 |
real time | 7 |
mild symptoms | 7 |
odds ratio | 7 |
significantly lower | 7 |
clinical management | 7 |
early transmission | 7 |
clinical course | 7 |
positive test | 7 |
coronavirus outbreak | 7 |
population size | 7 |
ndpm model | 7 |
national health | 7 |
global mortality | 7 |
known cases | 7 |
observational study | 7 |
among female | 7 |
available data | 7 |
epidemiologically derived | 6 |
remaining countries | 6 |
correction factor | 6 |
infection control | 6 |
effective intervention | 6 |
mortality due | 6 |
older populations | 6 |
respiratory distress | 6 |
conducted using | 6 |
reproductive number | 6 |
st march | 6 |
initial outbreak | 6 |
new disease | 6 |
human transmission | 6 |
underlying population | 6 |
driven analysis | 6 |
excess deaths | 6 |
may affect | 6 |
doubling days | 6 |
icu capacity | 6 |
average age | 6 |
estimated cfrs | 6 |
lessons learned | 6 |
case reports | 6 |
within days | 6 |
study reported | 6 |
detection rate | 6 |
estimated cases | 6 |
health service | 6 |
input variables | 6 |
global data | 6 |
cardiovascular disease | 6 |
relatively high | 6 |
disease prevention | 6 |
infectious period | 6 |
severe pandemics | 6 |
association analysis | 6 |
following covid | 6 |
first cases | 6 |
confirmed covid | 6 |
hazardous substances | 6 |
mitigation measures | 6 |
countries will | 6 |
observed cfr | 6 |
forecasted case | 6 |
ten days | 6 |
become infected | 6 |
mortality following | 6 |
rights reserved | 6 |
highest cfr | 6 |
symptomatic individuals | 6 |
case study | 6 |
critical care | 6 |
test fees | 6 |
china jan | 6 |
reported covid | 6 |
health workers | 6 |
hazardous materials | 6 |
school closures | 6 |
us cdc | 6 |
icu beds | 6 |
reported case | 6 |
severe illness | 6 |
future pandemic | 6 |
viral load | 6 |
real incidence | 6 |
highly pathogenic | 6 |
sample size | 6 |
disease surveillance | 6 |
high cases | 6 |
top countries | 6 |
cfr ar | 6 |
time periods | 6 |
several countries | 6 |
smoking prevalence | 6 |
young adults | 6 |
severity category | 6 |
series data | 6 |
critical cases | 6 |
post hoc | 6 |
posted july | 6 |
pneumoniae urinary | 6 |
protective effect | 6 |
pandemic costs | 6 |
cfr calculated | 6 |
recovered patients | 6 |
cases using | 6 |
oxygen therapy | 6 |
cfr among | 6 |
mortality burden | 6 |
see table | 6 |
reported cfr | 6 |
results suggest | 6 |
protection factor | 6 |
logistic model | 6 |
test pool | 6 |
million citizens | 6 |
past cases | 6 |
decision making | 6 |
european centre | 6 |
predicted cfr | 6 |
fold lower | 6 |
protocol eligibility | 6 |
transmission risk | 6 |
biological agents | 6 |
medical costs | 6 |
respiratory diseases | 6 |
underlying conditions | 5 |
early estimates | 5 |
deaths may | 5 |
lower slope | 5 |
error propagation | 5 |
last days | 5 |
per people | 5 |
subgroup analysis | 5 |
adjusted case | 5 |
travel restrictions | 5 |
country region | 5 |
closed cases | 5 |
west bengal | 5 |
policy makers | 5 |
five different | 5 |
fire services | 5 |
distribution analysis | 5 |
related death | 5 |
infected person | 5 |
input parameters | 5 |
law enforcement | 5 |
fatality risks | 5 |
positive correlation | 5 |
pandemic cost | 5 |
ppe must | 5 |
specific attack | 5 |
population data | 5 |
lower among | 5 |
data provided | 5 |
imported cases | 5 |
outside china | 5 |
results section | 5 |
healthcare facility | 5 |
current study | 5 |
relative death | 5 |
travel history | 5 |
respiratory pathogens | 5 |
higher severity | 5 |
dependent gender | 5 |
tumor necrosis | 5 |
specific mortality | 5 |
reproduction numbers | 5 |
viewpoints research | 5 |
epidemic models | 5 |
like illness | 5 |
significant correlation | 5 |
influenza pneumonia | 5 |
performed tests | 5 |
high number | 5 |
robust estimation | 5 |
supplementary document | 5 |
crude case | 5 |
patients received | 5 |
median age | 5 |
mathematical models | 5 |
high values | 5 |
study group | 5 |
delay times | 5 |
influenza mitigation | 5 |
modified logistic | 5 |
time forecasts | 5 |
april st | 5 |
relatively low | 5 |
estimating absolute | 5 |
healthcare costs | 5 |
global pandemic | 5 |
cfr estimate | 5 |
limit analysis | 5 |
research theme | 5 |
will die | 5 |
many cases | 5 |
first months | 5 |
real estimates | 5 |
healthcare facilities | 5 |
publicly reported | 5 |
cfr estimation | 5 |
north america | 5 |
respiratory disease | 5 |
cost per | 5 |
online supplementary | 5 |
sample forecasts | 5 |
physical distancing | 5 |
broad range | 5 |
higher mortality | 5 |
medical attention | 5 |
lactam alone | 5 |
much smaller | 5 |
world bank | 5 |
may lead | 5 |
methods section | 5 |
two groups | 5 |
potential conflicts | 5 |
sex differences | 5 |
ebola virus | 5 |
initial stages | 5 |
doubling intervals | 5 |
gross domestic | 5 |
antiviral drug | 5 |
also affect | 5 |
allowed us | 5 |
health emergencies | 5 |
expert consensus | 5 |
oldest age | 5 |
bcg vaccination | 5 |
disaster response | 5 |
diagnostic tests | 5 |
deaths due | 5 |
severe outcomes | 5 |
first reported | 5 |
top states | 5 |
many people | 5 |
countries using | 5 |
standard precautions | 5 |
immune responses | 5 |
polynomial growth | 5 |
may reduce | 5 |
findings suggest | 5 |
data collected | 5 |
descriptive study | 5 |
two different | 5 |
series datasets | 5 |
gamma distribution | 5 |
deaths among | 5 |
two parameters | 5 |
asymptomatic infections | 5 |
conditional probabilities | 5 |
cardiovascular diseases | 5 |
icu admission | 5 |
training data | 5 |
least registered | 5 |
causal effect | 5 |
hospital admission | 5 |
factors associated | 5 |
medically attended | 5 |
severe covid | 5 |
tested positive | 5 |
forecasting model | 5 |
personal fees | 5 |
much lower | 5 |
tokyo subway | 5 |
selected saarc | 5 |
cfr depends | 5 |
ongoing epidemic | 5 |
single death | 5 |
right truncation | 5 |
data collapse | 5 |
necrosis factor | 5 |
emergency department | 5 |
seir model | 5 |
cfr calculation | 5 |
three different | 5 |
influenza epidemics | 5 |
comparative study | 5 |
moderate risk | 5 |
countries like | 5 |
us states | 5 |
predicted values | 5 |
logistic regression | 5 |
based forecasting | 5 |
statistical significance | 5 |
antimicrobial therapy | 5 |
model parameters | 5 |
three studies | 5 |
growth rates | 5 |
cfr increased | 5 |
study design | 5 |
significant difference | 5 |
public gatherings | 5 |
national institute | 5 |
confirmed positive | 5 |
feb china | 5 |
susceptible individuals | 5 |
sample sizes | 5 |
linear fit | 5 |
overwhelmed health | 5 |
interactive web | 5 |
cost components | 5 |
emerging pandemic | 5 |
oxygen saturations | 5 |
new coronavirus | 5 |
pregnant women | 5 |
retrospective studies | 5 |
three investigators | 5 |
available case | 5 |
freedom ranking | 5 |
one step | 5 |
wide range | 5 |
supplemental table | 5 |
reported death | 5 |
excess mortality | 5 |
supplemental information | 4 |
infect dis | 4 |
air pollution | 4 |
hospital decontamination | 4 |
dis doi | 4 |
new jersey | 4 |
active cases | 4 |
growth models | 4 |
cases identified | 4 |
health status | 4 |
cases may | 4 |
using seroprevalence | 4 |
airborne precautions | 4 |
younger populations | 4 |
commonly used | 4 |
intervention measures | 4 |
transmission model | 4 |
give us | 4 |
oxygen saturation | 4 |
right now | 4 |
novel pathogen | 4 |
overall cost | 4 |
authors read | 4 |
mitigation efforts | 4 |
mortality figures | 4 |
higher values | 4 |
reported prevalence | 4 |
health promotion | 4 |
modelled community | 4 |
may experience | 4 |
medical personnel | 4 |
visual inspection | 4 |
linear relationship | 4 |
model using | 4 |
just like | 4 |
confirmed case | 4 |
daily cases | 4 |
productivity loss | 4 |
also used | 4 |
countries variance | 4 |
pneumonia caused | 4 |
containment measures | 4 |
community transmission | 4 |
statistical methods | 4 |
health services | 4 |
hold true | 4 |
health expenditure | 4 |
based dashboard | 4 |
low case | 4 |
control dynamics | 4 |
household members | 4 |
two countries | 4 |
early stages | 4 |
time since | 4 |
registered cases | 4 |
less effective | 4 |
observed ndpm | 4 |
cfrs varied | 4 |
time distribution | 4 |
time course | 4 |
calculated time | 4 |
significant heterogeneity | 4 |
human serum | 4 |
health management | 4 |
root mean | 4 |
oxygen policies | 4 |
death distributions | 4 |
level factors | 4 |
will occur | 4 |
million inhabitants | 4 |
track covid | 4 |
higher levels | 4 |
adjusted data | 4 |
effective potential | 4 |
reported outcomes | 4 |
protective suits | 4 |
till april | 4 |
pandemic clinical | 4 |
common cold | 4 |
complete data | 4 |
infection among | 4 |
will also | 4 |
ethical approval | 4 |
zika virus | 4 |
protective measures | 4 |
bacterial meningitis | 4 |
adverse events | 4 |
cfr will | 4 |
one country | 4 |
clinical outcome | 4 |
italian data | 4 |
proposed model | 4 |
epidemic modeling | 4 |
emerging influenza | 4 |
respiratory symptoms | 4 |
asymptomatic proportion | 4 |
different scenarios | 4 |
significantly higher | 4 |
tropical medicine | 4 |
certain date | 4 |
hospital personnel | 4 |
will provide | 4 |
respective countries | 4 |
day period | 4 |
test positive | 4 |
disease outbreaks | 4 |
warning level | 4 |
ordinal scores | 4 |
least two | 4 |
sarin attack | 4 |
italian ministry | 4 |
influenza transmission | 4 |
scaling factor | 4 |
study characteristics | 4 |
experimental results | 4 |
publisher full | 4 |
icu group | 4 |
explanatory variables | 4 |
also provide | 4 |
converting enzyme | 4 |
see process | 4 |
costs arising | 4 |
test results | 4 |
health estimates | 4 |
first quarter | 4 |
analyses using | 4 |
true number | 4 |
epidemic spreading | 4 |
model provides | 4 |
latent period | 4 |
male cases | 4 |
case report | 4 |
syncytial virus | 4 |
person compared | 4 |
geographic distribution | 4 |
western australia | 4 |
united nations | 4 |
selected countries | 4 |
belgium data | 4 |
ongoing covid | 4 |
use data | 4 |
took place | 4 |
domestic product | 4 |
potential growth | 4 |
cfr using | 4 |
open data | 4 |
becoming cases | 4 |
reported confirmed | 4 |
fatal patients | 4 |
lost productivity | 4 |
peak symptomatic | 4 |
test numbers | 4 |
disease transmission | 4 |
level data | 4 |
high accuracy | 4 |
national target | 4 |
face piece | 4 |
different data | 4 |
novel influenza | 4 |
fit method | 4 |
via contact | 4 |
appropriate ppe | 4 |
death among | 4 |
supplementary appendix | 4 |
sars coronavirus | 4 |
calculating cfr | 4 |
first death | 4 |
similar results | 4 |
supportive care | 4 |
significant association | 4 |
specific covid | 4 |
extensive research | 4 |
individual case | 4 |
various countries | 4 |
shed light | 4 |
year age | 4 |
possible explanation | 4 |
ppe may | 4 |
biological delay | 4 |
societal disruption | 4 |
using delay | 4 |
clinical data | 4 |
potential impact | 4 |
different regions | 4 |
individual states | 4 |
lower bound | 4 |
title abstract | 4 |
reproduction rate | 4 |
competing interests | 4 |
tests per | 4 |
generate short | 4 |
regression model | 4 |
median time | 4 |
reported incidence | 4 |
care workers | 4 |
reporting delays | 4 |
subway sarin | 4 |
infectious agents | 4 |
empiric therapy | 4 |
higher covid | 4 |
times higher | 4 |
country centroid | 4 |
antimicrobial agents | 4 |
authors declare | 4 |
death reporting | 4 |
oklahoma city | 4 |
may result | 4 |
coronavirus infection | 4 |
extensive testing | 4 |
error series | 4 |
model used | 4 |
systems science | 4 |
ecological study | 4 |
healthy contacts | 4 |
many estimates | 4 |
vast majority | 4 |
publication bias | 4 |
distress syndrome | 4 |
retrospective cohort | 4 |
adult inpatients | 4 |
data extraction | 4 |
extended data | 4 |
predict cfr | 4 |
country comparison | 4 |
excess death | 4 |
cephalosporin alone | 4 |
enforcement officers | 4 |
future studies | 4 |
statistical heterogeneity | 4 |
death interval | 4 |
bias assessments | 4 |
among male | 4 |
plasma may | 4 |
respiratory syncytial | 4 |
pandemic outbreak | 4 |
deaths caused | 4 |
malaria prevalence | 4 |
data point | 4 |
ranking measure | 4 |
antiviral costs | 4 |
three days | 4 |
basic assumptions | 4 |
quite different | 4 |
mortality estimates | 4 |
rigorous social | 4 |
day delay | 4 |
ongoing pandemic | 4 |
present study | 4 |
study clinical | 4 |
medical education | 4 |
china clinical | 4 |
true prevalence | 4 |
variable importance | 4 |
vary widely | 4 |
severe respiratory | 4 |
reporting bias | 4 |
factors affecting | 4 |
log relationship | 4 |
pandemics costs | 4 |
recently reported | 4 |
influenza epidemic | 4 |
short delay | 4 |
small sample | 4 |
sars outbreak | 4 |
sars showed | 4 |
york city | 4 |
coronavirus covid | 4 |
atypical pathogens | 4 |
ave i | 4 |
one study | 4 |
cfr value | 4 |
retrospective analysis | 4 |
controlled clinical | 4 |
exaggerated information | 4 |
optimal regression | 4 |
officially reported | 4 |
transmission rate | 4 |
total pandemic | 4 |
corona virus | 4 |
confounding factors | 4 |
across groups | 4 |
terminal number | 4 |
chemically protective | 4 |
comparator group | 4 |
three variables | 4 |
data mining | 4 |
rapidly evolving | 4 |
analysis will | 4 |
interval distribution | 4 |
will likely | 4 |
first estimates | 4 |
antiviral prophylaxis | 4 |
severe sepsis | 4 |
many days | 4 |
official reports | 4 |
situation reports | 4 |
although highly | 4 |
vaccine development | 4 |
health response | 4 |
several factors | 4 |
health decisions | 3 |
three time | 3 |
spo may | 3 |
wtc disaster | 3 |
beta distribution | 3 |
linear log | 3 |
cfr may | 3 |
may explain | 3 |
official reporting | 3 |
actual infections | 3 |
study using | 3 |
people will | 3 |
deaths occurred | 3 |
coronavirus pandemic | 3 |
excess covid | 3 |
tracking project | 3 |
costing model | 3 |
official information | 3 |
line charts | 3 |
age composition | 3 |
early estimate | 3 |
kano diagram | 3 |
respiratory infection | 3 |
made publicly | 3 |
copd prevalence | 3 |
causal agent | 3 |
conditional probability | 3 |
severity pandemic | 3 |
medical facilities | 3 |
tests conducted | 3 |
century pandemic | 3 |
respiratory protective | 3 |
events surveillance | 3 |
might also | 3 |
close contacts | 3 |
using age | 3 |
specific duration | 3 |
testing policy | 3 |
analysis date | 3 |
positively correlated | 3 |
aged years | 3 |
analysis methodology | 3 |
pneumoniae isolates | 3 |
mortality data | 3 |
day latent | 3 |
reported epg | 3 |
observational data | 3 |
received convalescent | 3 |
second problem | 3 |
similar findings | 3 |
rasch measurement | 3 |
current level | 3 |
mild disease | 3 |
maximum group | 3 |
respiratory illness | 3 |
younger population | 3 |
quality test | 3 |
reference source | 3 |
study highlights | 3 |
laboratory confirmation | 3 |
also examined | 3 |
cdc study | 3 |
local growth | 3 |
direct interest | 3 |
illness onset | 3 |
seroprevalence studies | 3 |
standard population | 3 |
posterior distribution | 3 |
outbreak size | 3 |
contact network | 3 |
recovered persons | 3 |
one week | 3 |
hardest hit | 3 |
lopinavir ritonavir | 3 |
supplementary materials | 3 |
epidemic model | 3 |
symptomatic case | 3 |
squared error | 3 |
seek medical | 3 |
million persons | 3 |
lateral sclerosis | 3 |
versus severe | 3 |
estimating case | 3 |
first problem | 3 |
hazmat releases | 3 |
times greater | 3 |
one hundred | 3 |
highest number | 3 |
study also | 3 |
service industry | 3 |
cases data | 3 |
complete datasets | 3 |
mean difference | 3 |
inflection point | 3 |
epidemic curves | 3 |
significant reduction | 3 |
future productivity | 3 |
current health | 3 |
respiratory viruses | 3 |
deceased patients | 3 |
health notices | 3 |
fold higher | 3 |
less biased | 3 |
will typically | 3 |
travel advisories | 3 |
cfr measure | 3 |
expected number | 3 |
health research | 3 |
obtain reliable | 3 |
community contacts | 3 |
preprintthe copyright | 3 |
two cohort | 3 |
national case | 3 |
wuhan city | 3 |
older individuals | 3 |
atypical coverage | 3 |
published studies | 3 |
detailed modeling | 3 |
crude covid | 3 |
likely due | 3 |
potential risk | 3 |
substantial undocumented | 3 |
mortality impact | 3 |
centroid latitude | 3 |
median interval | 3 |
symptomatic people | 3 |
related susceptibility | 3 |
health agencies | 3 |
economic impact | 3 |
among women | 3 |
elderly patients | 3 |
epidemic spread | 3 |
observed case | 3 |
males compared | 3 |
study conducted | 3 |
epidemic curve | 3 |
correcting hypoxia | 3 |
neutralizing antibody | 3 |
older population | 3 |
influenza strain | 3 |
calculated according | 3 |
diabetes mellitus | 3 |
data availability | 3 |
saudi arabia | 3 |
table ii | 3 |
hospital stay | 3 |
earlier stages | 3 |
susceptible persons | 3 |
calculated using | 3 |
istituto superiore | 3 |
gather data | 3 |
patients presented | 3 |
suspected cases | 3 |
registered covid | 3 |
convalescent blood | 3 |
overall ar | 3 |
suppression strategies | 3 |
five days | 3 |
term care | 3 |
normalised cfr | 3 |
square error | 3 |
oxygen levels | 3 |
growth phase | 3 |
day cycle | 3 |
event history | 3 |
influenza cases | 3 |
moving average | 3 |
also provided | 3 |
global response | 3 |
murine pneumococcal | 3 |
information system | 3 |
will take | 3 |
data entries | 3 |
chinese center | 3 |
care facilities | 3 |
extracorporeal membrane | 3 |
one must | 3 |
morbid persons | 3 |
diagonal line | 3 |
death count | 3 |
key parameters | 3 |
testing capacities | 3 |
better management | 3 |
outcome measures | 3 |
component models | 3 |
including studies | 3 |
trend test | 3 |
net benefit | 3 |
epidemic may | 3 |
constant doubling | 3 |
similar log | 3 |
emergency events | 3 |
among patients | 3 |
done using | 3 |
lower part | 3 |
highly significantly | 3 |
medical conditions | 3 |
account detection | 3 |
world population | 3 |
disease burden | 3 |
patient decontamination | 3 |
i thank | 3 |
studies included | 3 |
may help | 3 |
igg antibodies | 3 |
order polynomial | 3 |
cytokine storm | 3 |
different groups | 3 |
first study | 3 |
breathing apparatus | 3 |
journal pre | 3 |
asymptomatic infection | 3 |
intravenous immunoglobulin | 3 |
remained significant | 3 |
public policy | 3 |
undocumented infection | 3 |
inverse relation | 3 |
data used | 3 |
respiratory system | 3 |
substances emergency | 3 |
abductive reasoning | 3 |
transparent health | 3 |
results indicate | 3 |
beds per | 3 |
estimate cfr | 3 |
changes associated | 3 |
case studies | 3 |
pandemic response | 3 |
reducing mortality | 3 |
multiple countries | 3 |
also considered | 3 |
chemical warfare | 3 |
better understand | 3 |
contained breathing | 3 |
estimated effective | 3 |
prevent transmission | 3 |
lag time | 3 |
studies suggest | 3 |
model predicts | 3 |
old age | 3 |
global average | 3 |
preprint posted | 3 |
multivariate logistic | 3 |
current situation | 3 |
rd scales | 3 |
different centers | 3 |
low cost | 3 |
pandemic using | 3 |
hospitalization will | 3 |
different delays | 3 |
surveillance database | 3 |
high end | 3 |
epidemic sizes | 3 |
database will | 3 |
many patients | 3 |
real number | 3 |
reported number | 3 |
covid cases | 3 |
three independent | 3 |
parameter settings | 3 |
cfr appears | 3 |
corona viruses | 3 |
seeking medical | 3 |
age cohort | 3 |
clinical diagnosis | 3 |
commencing oxygen | 3 |
ratio estimates | 3 |
quality control | 3 |
ongoing clinical | 3 |
amyotrophic lateral | 3 |
hybrid methodology | 3 |
documented cases | 3 |
mean square | 3 |
risk posed | 3 |
many factors | 3 |
cause mortality | 3 |
may contribute | 3 |
significant absolute | 3 |
risk assessments | 3 |
elder population | 3 |
death cases | 3 |
requiring hospitalization | 3 |
will therefore | 3 |
case scenario | 3 |
healthcare systems | 3 |
services personnel | 3 |
elderly people | 3 |
bias due | 3 |
rapid dissemination | 3 |
profoundly affected | 3 |
middle income | 3 |
important lessons | 3 |
patients receiving | 3 |
early epidemiological | 3 |
log age | 3 |
possible causal | 3 |
deaths will | 3 |
useful information | 3 |
series analysis | 3 |
became cases | 3 |
viral infections | 3 |
true value | 3 |
health doi | 3 |
final toll | 3 |
may th | 3 |
final attack | 3 |
lognormal distribution | 3 |
clinical experience | 3 |
severe chronic | 3 |
projected cumulative | 3 |
cases due | 3 |
many states | 3 |
allows us | 3 |
source population | 3 |
following treatment | 3 |
data sets | 3 |
initial phase | 3 |
daily tweets | 3 |
late february | 3 |
retrospective case | 3 |
posted online | 3 |
cases versus | 3 |
international health | 3 |
recent study | 3 |
early treatment | 3 |
less ndpm | 3 |
overall slope | 3 |
female population | 3 |
unknown cause | 3 |
purifying respirator | 3 |
sp nov | 3 |
respiratory viral | 3 |
average number | 3 |
deaths divided | 3 |
reported positive | 3 |
exploratory meta | 3 |
occupational safety | 3 |
first day | 3 |
dead patients | 3 |
response workers | 3 |
severe outbreaks | 3 |
new location | 3 |
early findings | 3 |
emergency responders | 3 |
legionella species | 3 |
air supply | 3 |
shiny app | 3 |
outbreak using | 3 |
gather statement | 3 |
highly affected | 3 |
much greater | 3 |
history modelling | 3 |
testing figures | 3 |
three weeks | 3 |
cases worldwide | 3 |
osha guidance | 3 |
true epidemic | 3 |
south africa | 3 |
estimates reporting | 3 |
markedly different | 3 |
human influenza | 3 |
infectious individual | 3 |
including school | 3 |
healthcare providers | 3 |
clinical assessment | 3 |
time lags | 3 |
coronavirus cases | 3 |
closure combined | 3 |
essential causal | 3 |
neuraminidase inhibitors | 3 |
south asian | 3 |
southern hemisphere | 3 |
susceptible population | 3 |
organ failure | 3 |
hemorrhagic fever | 3 |
better estimate | 3 |
mortality among | 3 |
scaling time | 3 |
group size | 3 |
within countries | 3 |
infection mortality | 3 |
simple linear | 3 |
surveillance system | 3 |
italian population | 3 |
chronic obstructive | 3 |
must take | 3 |
negative patients | 3 |
deaths counts | 3 |
adverse health | 3 |
additional delay | 3 |
predicted log | 3 |
much better | 3 |
personal communication | 3 |
epidemiological determinants | 3 |
comparative data | 3 |
insight data | 3 |
related mortality | 3 |
days ahead | 3 |
death given | 3 |
estimated cumulative | 3 |
detection delay | 3 |
interval adjusted | 3 |
decomposition levels | 3 |
different states | 3 |
decontamination activities | 3 |
positively associated | 3 |
chronic conditions | 3 |
health metrics | 3 |
underreported cases | 3 |
unofficial data | 3 |
inclusion criteria | 3 |
mean age | 3 |
adjusted post | 3 |
wider community | 3 |
second wave | 3 |
unconfirmed death | 3 |
powered air | 3 |
chronic respiratory | 3 |
cfrs based | 3 |
will cause | 3 |
may occur | 3 |
per se | 3 |
health surveillance | 3 |
cost analysis | 3 |
cases detected | 3 |
nonpharmaceutical interventions | 3 |
among adults | 3 |
causal impact | 3 |
essential businesses | 3 |
relatively mild | 3 |
will affect | 3 |
young people | 3 |
deficient mice | 3 |
also estimated | 3 |
total case | 3 |
higher attack | 3 |
using ppe | 3 |
online rasch | 3 |
symptomatic infectiousness | 3 |
testing strategy | 3 |
different populations | 3 |
policy response | 3 |
clinical findings | 3 |
estimations might | 3 |
first days | 3 |
new data | 3 |
every year | 3 |
genetic factors | 3 |
cdc travel | 3 |
best estimations | 3 |
affect cfr | 3 |
across different | 3 |
demographic structure | 3 |
lockdown period | 3 |
chemical protective | 3 |
total community | 3 |
proper use | 3 |
among hospitalized | 3 |
death toll | 3 |
pdm virus | 3 |
gradual slowing | 3 |
cases days | 3 |
comparative analyses | 3 |
cumulative death | 3 |
junyi zheng | 3 |
five pandemic | 3 |
testing rates | 3 |
clinical guidelines | 3 |
biases described | 3 |
distortion factor | 3 |
heat stress | 3 |
positive patients | 3 |
modeling approaches | 3 |
may reflect | 3 |
mean delay | 3 |
beneficial effect | 3 |
superiore di | 3 |
waste operations | 3 |
increased total | 3 |
enough testing | 3 |
days since | 3 |
analysis using | 3 |
sufficiently flexible | 3 |
membrane oxygenation | 3 |
lower left | 3 |
different european | 3 |
cases among | 3 |
antiviral interventions | 3 |
univariate analyses | 3 |
retrospective study | 3 |
detailed description | 3 |
using statistical | 3 |
mortalities considering | 3 |
risk ratio | 3 |
individual studies | 3 |
higher prevalence | 3 |
statistical computing | 3 |
global clinical | 3 |
countries date | 3 |
future covid | 3 |
community infections | 3 |
real data | 3 |
extreme measures | 3 |
hand hygiene | 3 |
prevent infection | 3 |
cfr reported | 3 |
pulmonary disease | 3 |
similar analyses | 3 |
infection facilitates | 3 |
age ranging | 3 |
pneumococcal disease | 3 |
epidemiological features | 3 |
true infection | 3 |
epidemic dynamics | 3 |
deaths related | 3 |
estimated global | 3 |
gendered impacts | 3 |
values around | 3 |
rate increases | 3 |
also calculated | 3 |
test rate | 3 |
two investigators | 3 |
surveillance pyramid | 3 |
lower case | 3 |
might shift | 3 |
hazardous waste | 3 |
almost complete | 3 |
also confirmed | 3 |
country variation | 3 |
terrorist attacks | 3 |
analysis method | 3 |
specific covariates | 3 |
increased cfr | 3 |
cumulative mortality | 3 |
analyzed data | 3 |
showed quite | 3 |
average cfr | 3 |
best fit | 3 |
may vary | 3 |
mycoplasma pneumoniae | 3 |
specific death | 3 |
multistep process | 3 |
strong correlation | 3 |
highly unlikely | 3 |
tree model | 3 |
research network | 3 |
outcomes across | 3 |
lowest cfr | 3 |
pandemic potential | 3 |
older adults | 3 |
rate using | 3 |
ppe selection | 3 |
normal distribution | 3 |
mental health | 3 |
epidemic doubling | 3 |
geographical regions | 3 |
low risk | 3 |
early march | 3 |
viral infection | 3 |
crucial importance | 3 |
ncov outbreak | 3 |
whereas others | 3 |
influenza showed | 3 |
various reasons | 3 |
farmer worker | 3 |
case ascertainment | 3 |
transmission characteristics | 3 |
white house | 3 |
calculated ifr | 3 |
several ways | 3 |
burden estimates | 3 |
controlled trials | 3 |
fatalities due | 3 |
control variables | 3 |
five datasets | 3 |
care resources | 3 |
multistep pattern | 3 |
cfr model | 3 |
study showed | 3 |
limited data | 3 |
mean number | 3 |
higher number | 3 |
previous study | 3 |
cfr growth | 3 |
european country | 3 |
reported use | 3 |
washington model | 3 |
epidemic wave | 3 |
specific cfr | 3 |
linear model | 3 |
model predictions | 3 |
current knowledge | 3 |
one particular | 3 |
epidemiology team | 3 |
severity level | 3 |
cumulative total | 3 |
detected cases | 3 |
poor health | 3 |
three groups | 3 |
london school | 3 |
dengue outbreaks | 3 |
costs ranging | 3 |
larger population | 3 |
aggregate data | 3 |
among cases | 3 |
unobserved cases | 3 |
disease characteristics | 3 |
serious adverse | 3 |
time varying | 3 |
several retrospective | 3 |
disease progression | 3 |
global economy | 3 |
response epidemiology | 3 |
widely varying | 3 |
first symptoms | 3 |
icu patients | 3 |
lower severity | 3 |
epidemy duration | 3 |
care costs | 3 |
possibly due | 3 |
important factor | 3 |
hybrid approach | 3 |
association due | 3 |
antibody seroprevalence | 3 |
available elsewhere | 3 |
reporting systems | 3 |
senior citizens | 3 |
constant cfr | 3 |
test figures | 3 |
pneumonia emergency | 3 |
foreign nationals | 3 |
widely available | 3 |
general public | 3 |
hot spots | 3 |
ff studies | 3 |
february th | 3 |
hazardous substance | 3 |
significantly affect | 3 |
close contact | 3 |
final manuscript | 3 |
lower respiratory | 3 |
influenza vaccination | 3 |
four days | 3 |
medical worker | 3 |
glamor project | 3 |
predicted ndpm | 3 |
male differences | 3 |
adult patients | 3 |
health regulations | 3 |
lower incidence | 3 |
household prophylaxis | 3 |
log scale | 3 |
data included | 3 |
health threat | 3 |
survey data | 3 |
different treatment | 3 |
dashed lines | 2 |
day asymptomatic | 2 |
nab titters | 2 |
severity estimates | 2 |
potential association | 2 |
first identified | 2 |
three states | 2 |
may account | 2 |
univariate time | 2 |
generate aerosols | 2 |
immune support | 2 |
community spread | 2 |
health policies | 2 |
italian case | 2 |
nonbacteremic pneumococcal | 2 |
pandemic cfr | 2 |
face masks | 2 |
actual cfr | 2 |
readily made | 2 |
health officer | 2 |
contaminated casualties | 2 |
small studies | 2 |
mathematical epidemic | 2 |
march st | 2 |
difference might | 2 |
medical authorities | 2 |
temporal dynamics | 2 |
national levels | 2 |
statistical learning | 2 |
kx wvw | 2 |
positive bias | 2 |
slower growth | 2 |
recent years | 2 |
potentially important | 2 |
macrolide antimicrobial | 2 |
measurement problems | 2 |
publication year | 2 |
asymptomatic infectiousness | 2 |
alternative parameter | 2 |
hospitalization rates | 2 |
different relationship | 2 |
following data | 2 |
protective ensemble | 2 |
taken care | 2 |
two states | 2 |
time points | 2 |
critical parameters | 2 |
rates across | 2 |
average time | 2 |
become time | 2 |
hospitalization given | 2 |
emergency mode | 2 |
john hopkins | 2 |
ottawa scale | 2 |
study estimates | 2 |
influenza simulation | 2 |
specific time | 2 |
municipal council | 2 |
national data | 2 |
objectively observed | 2 |
spike protein | 2 |
cfr computed | 2 |
symptoms appear | 2 |
three months | 2 |
narrative synthesis | 2 |
highest case | 2 |
natural science | 2 |
countries due | 2 |
respirators must | 2 |
randomized controlled | 2 |
bloodborne pathogens | 2 |
air source | 2 |
negative binomial | 2 |
march nationwide | 2 |
caution given | 2 |
nan sha | 2 |
country may | 2 |
management explanation | 2 |
higher cdr | 2 |
three countries | 2 |
epidemics using | 2 |
similar effects | 2 |
intervention costs | 2 |
fourteen countries | 2 |
trust surveillance | 2 |
nonlinear time | 2 |
prior pdf | 2 |
time point | 2 |
bias will | 2 |
statistically significance | 2 |
ambient air | 2 |
logit scores | 2 |
hospitalisation costs | 2 |
recent analysis | 2 |
time horizon | 2 |
around days | 2 |
discharged within | 2 |
declared covid | 2 |
pneumoniae infections | 2 |
infections may | 2 |
science foundation | 2 |
generally regarded | 2 |
taken place | 2 |
among different | 2 |
protective gear | 2 |
serological testing | 2 |
local information | 2 |
help us | 2 |
health problem | 2 |
month later | 2 |
mar singapore | 2 |
world trade | 2 |
test frequencies | 2 |
trouble one | 2 |
currently infected | 2 |
china sex | 2 |
antibody levels | 2 |
adult ph | 2 |
articles related | 2 |
novel covid | 2 |
based pandemic | 2 |
rasch modeling | 2 |
unequal variance | 2 |
estimated attack | 2 |
final dataset | 2 |
stimulus bill | 2 |
communityacquired pneumonia | 2 |
front torso | 2 |
weaker health | 2 |
cdr accounted | 2 |
informed consent | 2 |
knowledge regarding | 2 |
easy interpretability | 2 |
consumer price | 2 |
surveillance program | 2 |
high rate | 2 |
significant global | 2 |
consensus amongst | 2 |
involving patients | 2 |
recent days | 2 |
particular country | 2 |
parametric mixture | 2 |
logarithm function | 2 |
accurate cfr | 2 |
curfew laws | 2 |
random community | 2 |
simulated cases | 2 |
updated understanding | 2 |
colorectal cancer | 2 |
time may | 2 |
provide much | 2 |
fulfilled inclusion | 2 |
substantially decreased | 2 |
intense inflammatory | 2 |
transmission risks | 2 |
positive scenario | 2 |
younger age | 2 |
first confirmed | 2 |
cases datasets | 2 |
interventions incur | 2 |
linear regressions | 2 |
exaggerated immune | 2 |
might wish | 2 |
good measure | 2 |
field conditions | 2 |
summary statistics | 2 |
psychological effects | 2 |
healthcare service | 2 |
correct case | 2 |
per course | 2 |
first step | 2 |
care provider | 2 |
close monitoring | 2 |
korean society | 2 |
ncov working | 2 |
positive inpatients | 2 |
coronavirus may | 2 |
influenza seasons | 2 |
usually mild | 2 |
current estimates | 2 |
health concern | 2 |
longer delay | 2 |
year mortality | 2 |
five regions | 2 |
seven causal | 2 |
air via | 2 |
earlier estimates | 2 |
different testing | 2 |
vary depending | 2 |
case diagnosis | 2 |
high transmission | 2 |
vital surveillances | 2 |
hoc meta | 2 |
potential domestic | 2 |
significant interest | 2 |
medical services | 2 |
decontamination teams | 2 |
emergency oxygen | 2 |
i ozygkp | 2 |
clinical decision | 2 |
generates two | 2 |
health planning | 2 |
study aims | 2 |
risk difference | 2 |
time courses | 2 |
two factors | 2 |
presented hypoxic | 2 |
causal inference | 2 |
per mill | 2 |
investigated covid | 2 |
logistical function | 2 |
cause death | 2 |
following formula | 2 |
pubmed abstract | 2 |
cross validate | 2 |
granulocyte colony | 2 |
associated pneumonia | 2 |
includes asymptomatic | 2 |
ems personnel | 2 |
theoretical scenarios | 2 |
explain ndpm | 2 |
disproportionately impacts | 2 |
influenza types | 2 |
joint commission | 2 |
case will | 2 |
indirect effect | 2 |
still needs | 2 |
reduce mortality | 2 |
overseas territories | 2 |
peak period | 2 |
strongly correlated | 2 |
small community | 2 |
one third | 2 |
three scenarios | 2 |
independent estimates | 2 |
reducing epidemic | 2 |
treatment center | 2 |
early growth | 2 |
ey eo | 2 |
uniform unbiased | 2 |
cost data | 2 |
army center | 2 |
long period | 2 |
improve estimates | 2 |
creative commons | 2 |
genetically modified | 2 |
underestimated due | 2 |
decomposition level | 2 |
comparator country | 2 |
unclear whether | 2 |
may play | 2 |
three case | 2 |
community settings | 2 |
singapore jan | 2 |
potential confounders | 2 |
rate multiplier | 2 |
states estimated | 2 |
infectiousness timeline | 2 |
constructed using | 2 |
contacts within | 2 |
aforementioned risk | 2 |
infants aged | 2 |
reducing transmission | 2 |
category pandemic | 2 |
predicted mortality | 2 |
lung injury | 2 |
supplementary information | 2 |
representative sample | 2 |
much shorter | 2 |
may change | 2 |
three sources | 2 |
possible death | 2 |
major public | 2 |
post analysis | 2 |
appropriate protection | 2 |
specific outbreak | 2 |
several years | 2 |
cap include | 2 |
emerging literature | 2 |
relative risk | 2 |
coronavirus stimulus | 2 |
interesting case | 2 |
important number | 2 |
stages involved | 2 |
icu treatment | 2 |
higher death | 2 |
sex based | 2 |
secondary transmissions | 2 |
reasons including | 2 |
start date | 2 |
delay distribution | 2 |
day night | 2 |
large range | 2 |
rasch logit | 2 |
outbreak risks | 2 |
reducing pandemic | 2 |
analyzed countries | 2 |
model captures | 2 |
forecasting techniques | 2 |
points came | 2 |
use different | 2 |
possible reason | 2 |
exposed group | 2 |
com indrajitg | 2 |
first report | 2 |
cases occurring | 2 |
task force | 2 |
another one | 2 |
community acquired | 2 |
based approach | 2 |
clinical site | 2 |
based models | 2 |
admissions may | 2 |
predictive performance | 2 |
might lead | 2 |
individuals recover | 2 |
main text | 2 |
serology study | 2 |
modern forecasting | 2 |
medical evidence | 2 |
chinese locations | 2 |
patients without | 2 |
cases still | 2 |
whereas many | 2 |
biased towards | 2 |
excluding studies | 2 |
decontamination response | 2 |
new virus | 2 |
community mitigation | 2 |
group receiving | 2 |
pcr testing | 2 |
comparison study | 2 |
purely social | 2 |
treatment centers | 2 |
unknown error | 2 |
beds needed | 2 |
consistently high | 2 |
local government | 2 |
rate across | 2 |
recent seroprevalence | 2 |
adults hospitalized | 2 |
influenza economic | 2 |
potential travel | 2 |
triage systems | 2 |
transformed gdp | 2 |
bangladesh government | 2 |
reported mortality | 2 |
overall cfrs | 2 |
event training | 2 |
lancet infectious | 2 |
mixture model | 2 |
apparent delay | 2 |
multivariate linear | 2 |
limited clinical | 2 |
pneumococcal meningitis | 2 |
chemical terrorism | 2 |
interpreted parameters | 2 |
new burden | 2 |
unbiased nature | 2 |
countries starting | 2 |
analyses revealed | 2 |
clearly needed | 2 |
cross validated | 2 |
disease without | 2 |
influenza infection | 2 |
true measure | 2 |
monoclonal antibody | 2 |
influenza baseline | 2 |
clinical manifestations | 2 |
statistical method | 2 |
followed prospectively | 2 |
much trouble | 2 |
prevalence factor | 2 |
based model | 2 |
confirmed data | 2 |
time due | 2 |
requires data | 2 |
epidemic intensity | 2 |
education fund | 2 |
army soldier | 2 |
effective reproductive | 2 |
disease severe | 2 |
marginal utility | 2 |
testing policies | 2 |
incomplete data | 2 |
institutional review | 2 |
maximum likelihood | 2 |
data suggest | 2 |
chemical agents | 2 |
series generated | 2 |
official sources | 2 |
opening remarks | 2 |
three distinctive | 2 |
significantly older | 2 |
building bombing | 2 |
death numbers | 2 |
distinct age | 2 |
make sure | 2 |
capital city | 2 |
test hypothesis | 2 |
us state | 2 |
wavelet transform | 2 |
figures calculated | 2 |
younger people | 2 |
go back | 2 |
antiviral efficacy | 2 |
recommended target | 2 |
corrected cfr | 2 |
prospective observational | 2 |
nonstationary time | 2 |
panic shopping | 2 |
obstructive pulmonary | 2 |
will need | 2 |
east asia | 2 |
comparing mortality | 2 |
positive pressure | 2 |
new health | 2 |
study date | 2 |
year prospective | 2 |
different reasons | 2 |
inductive statistical | 2 |
reduce medical | 2 |
preventive measures | 2 |
costs dominate | 2 |
earliest estimate | 2 |
decision boundaries | 2 |
baseline seasons | 2 |
young women | 2 |
seasonal epidemics | 2 |
estimating clinical | 2 |
clinical improvement | 2 |
provoke coughing | 2 |
countries examined | 2 |
negative values | 2 |
surveillance rather | 2 |
health commission | 2 |
deaths globally | 2 |
grey literature | 2 |
illness costs | 2 |
vastly different | 2 |
small proportion | 2 |
national events | 2 |
quantitative analysis | 2 |
care personnel | 2 |
ten logarithmic | 2 |
new infections | 2 |
multivariable analysis | 2 |
pneumococcal resistance | 2 |
form i | 2 |
inverse correlation | 2 |
maximum correlation | 2 |
relative days | 2 |
excluded due | 2 |
tn muv | 2 |
chronic disease | 2 |
likelihood method | 2 |
int log | 2 |
two reviewers | 2 |
growing number | 2 |
hiv trials | 2 |
whether children | 2 |
higher case | 2 |
related information | 2 |
unemployed persons | 2 |
secondary infections | 2 |
demonstrated significant | 2 |
linearly scaled | 2 |
respiratory virus | 2 |
average length | 2 |
pandemic shows | 2 |
outbreak situation | 2 |
much still | 2 |
mortality variance | 2 |
demographic adjustment | 2 |
youngest nations | 2 |
national guideline | 2 |
antimicrobial agent | 2 |
modulating activity | 2 |
study since | 2 |
higher total | 2 |
fitting face | 2 |
coronavirus deaths | 2 |
older patients | 2 |
new outbreaks | 2 |
initial outbreaks | 2 |
italian one | 2 |
cases might | 2 |
disease outcome | 2 |
average population | 2 |
first peak | 2 |
analysis across | 2 |
two antibiotics | 2 |
published estimates | 2 |
greater risk | 2 |
responder injuries | 2 |
generate timely | 2 |
imported infections | 2 |
prediction intervals | 2 |
loss due | 2 |
maximum infectiousness | 2 |
vary significantly | 2 |
cost results | 2 |
ensure better | 2 |
rate parameter | 2 |
false claims | 2 |
decontamination room | 2 |
different estimates | 2 |
stratification criteria | 2 |
pooled analysis | 2 |
following seven | 2 |
including japan | 2 |
roughly constant | 2 |
school day | 2 |
taylor series | 2 |
interim pre | 2 |
observed criteria | 2 |
rt model | 2 |
case enters | 2 |
novel therapies | 2 |
sarin vapor | 2 |
individuals die | 2 |
may apply | 2 |
many months | 2 |
data reporting | 2 |
mechanisms explaining | 2 |
simple approach | 2 |
world war | 2 |
becomes imperative | 2 |
progressively increased | 2 |
initial estimates | 2 |
will probably | 2 |
lower mortality | 2 |
increased physical | 2 |
online sources | 2 |
mass destruction | 2 |
model assumptions | 2 |
pneumoniae infection | 2 |
cfr accurately | 2 |
zl url | 2 |
cumulative changes | 2 |
period analyzed | 2 |
explicitly accounts | 2 |
hazmat response | 2 |
initial rapid | 2 |
patients admitted | 2 |
elderly age | 2 |
observed differences | 2 |
rank correlation | 2 |
limited duration | 2 |
will avoid | 2 |
traditional time | 2 |
previous modelling | 2 |
long duration | 2 |
autocorrelation function | 2 |
community strategy | 2 |
will come | 2 |
require extensive | 2 |
distancing strategies | 2 |
care activities | 2 |
highly contagious | 2 |
illness attack | 2 |
fatality estimates | 2 |
high impacts | 2 |
significant level | 2 |
will keep | 2 |
strategy combining | 2 |
clinical effectiveness | 2 |
high value | 2 |
baseline health | 2 |
treatment facilities | 2 |
epidemiological indicators | 2 |
directly applicable | 2 |
control strategies | 2 |
sectional study | 2 |
optimal oxygen | 2 |
parameters calculated | 2 |
unknown extend | 2 |
best available | 2 |
evolving disease | 2 |
similar time | 2 |
flu recruits | 2 |
zone activities | 2 |
implementing oxygen | 2 |
serological surveys | 2 |
early reported | 2 |
similar measures | 2 |
total infected | 2 |
sars data | 2 |
worse outcomes | 2 |
china data | 2 |
specific infection | 2 |
messages regarding | 2 |
receiving atypical | 2 |
three models | 2 |
daily basis | 2 |
already infected | 2 |
current context | 2 |
ascertainment bias | 2 |
acf plot | 2 |
control covid | 2 |
specific number | 2 |
ncov infection | 2 |
interventions resulted | 2 |
like italy | 2 |
clear risk | 2 |
short period | 2 |
resources available | 2 |
nonsignificant absolute | 2 |
one possible | 2 |
release zone | 2 |
rapid rise | 2 |
correctly identified | 2 |
received funding | 2 |
confirmed influenza | 2 |
average wages | 2 |
causally related | 2 |
cid ciaa | 2 |
moderate source | 2 |
simple half | 2 |
obtained data | 2 |
studies mentioned | 2 |
resulting societal | 2 |
versus treatment | 2 |
optimal target | 2 |
many infections | 2 |
incremental cost | 2 |
potential fatality | 2 |
time will | 2 |
hiv infection | 2 |
viral replication | 2 |
specific antibodies | 2 |
pearson correlation | 2 |
perhaps indicating | 2 |
icu admissions | 2 |
either continuous | 2 |
wavelet transformation | 2 |
developing stage | 2 |
decontamination team | 2 |
cumulated number | 2 |
provided visual | 2 |
io visualisations | 2 |
affected patients | 2 |
million cases | 2 |
i believe | 2 |
little evidence | 2 |
caused secondary | 2 |
hybrid models | 2 |
average decrease | 2 |
seroepidemiological study | 2 |
generate required | 2 |
fresh air | 2 |
religious events | 2 |
control groups | 2 |
shutdown period | 2 |
make contacts | 2 |
among others | 2 |
pandemic scenarios | 2 |
minimum level | 2 |
may involve | 2 |
seasonal flu | 2 |
normalised ndpm | 2 |
presented using | 2 |
opposite direction | 2 |
clear whether | 2 |
will usually | 2 |
ethical issues | 2 |
recent estimates | 2 |
designed clinical | 2 |
international concern | 2 |
received empiric | 2 |
chemical release | 2 |
recent experimental | 2 |
physical hazards | 2 |
increased severity | 2 |
address public | 2 |
average projected | 2 |
severe enough | 2 |
suitable interventions | 2 |
biallelic expression | 2 |
economic evaluation | 2 |
positive individuals | 2 |
treatment may | 2 |
sock type | 2 |
observed deaths | 2 |
male difference | 2 |
data recorded | 2 |
strongly dependent | 2 |
mortality outcome | 2 |
studies involving | 2 |
pandemic mitigation | 2 |
nationwide lockdown | 2 |
care centers | 2 |
reached statistical | 2 |
extended school | 2 |
potentially infectious | 2 |
data source | 2 |
waveform similarity | 2 |
influenza clinical | 2 |
different approaches | 2 |
another study | 2 |
calculated case | 2 |
implemented conservative | 2 |
inadequate testing | 2 |
reliable data | 2 |
asymptomatic among | 2 |
attended cfr | 2 |
site corrects | 2 |
mildly affected | 2 |
cost ranges | 2 |
mean attack | 2 |
one cohort | 2 |
septic shock | 2 |
special reference | 2 |
relatively lower | 2 |
higher mean | 2 |
nationwide analysis | 2 |
interesting patterns | 2 |
obtained using | 2 |
government officials | 2 |
revised downward | 2 |
night periods | 2 |
chinese one | 2 |
global hiv | 2 |
vary markedly | 2 |
significant proportion | 2 |
risk population | 2 |
anthrax incidents | 2 |
countries shown | 2 |
provided evidences | 2 |
methodological heterogeneity | 2 |
current outbreak | 2 |
daily new | 2 |
testing pool | 2 |
natural history | 2 |
discourage unnecessary | 2 |
data underlying | 2 |
another risk | 2 |
relationship may | 2 |
international prospective | 2 |
including one | 2 |
health sciences | 2 |
infection reported | 2 |
incidence will | 2 |
right panel | 2 |
treat spanish | 2 |
randomized trial | 2 |
negative bias | 2 |
rates lower | 2 |
randomly chosen | 2 |
accurate indicators | 2 |
reports reported | 2 |
qr codes | 2 |
logarithmic transformation | 2 |
possible relationship | 2 |
hospital staff | 2 |
significantly improve | 2 |
general overview | 2 |
identical epidemic | 2 |
social media | 2 |
typically leading | 2 |
test result | 2 |
proper communication | 2 |
also conducted | 2 |
increased temperature | 2 |
continuous workforce | 2 |
per student | 2 |
air bottle | 2 |
global testing | 2 |
also increase | 2 |
federal building | 2 |
strict lockdowns | 2 |
mode case | 2 |
three age | 2 |
national emergency | 2 |
comparing data | 2 |
lower right | 2 |
infection alone | 2 |
countries studied | 2 |
treatment effects | 2 |
individual countries | 2 |
given hospitalization | 2 |
states census | 2 |
reported epidemic | 2 |
major harm | 2 |
may require | 2 |
long follow | 2 |
people might | 2 |
pandemic definition | 2 |
people diagnosed | 2 |
cfr based | 2 |
easily included | 2 |
first time | 2 |
gatherings including | 2 |
severe clinical | 2 |
biases may | 2 |
central government | 2 |
whether observed | 2 |
suspected influenza | 2 |
best practices | 2 |
adjusted coefficient | 2 |
infectivity profile | 2 |
multivariate analysis | 2 |
weak negative | 2 |
actually positive | 2 |
detailed analysis | 2 |
hsees data | 2 |
chennai among | 2 |
correct death | 2 |
prevalence studies | 2 |
theoretically expected | 2 |
abrasion resistance | 2 |
oil resistant | 2 |
well enough | 2 |